Marie Thibault
Stock Analyst at BTIG
(3.35)
# 996
Out of 5,157 analysts
116
Total ratings
45.05%
Success rate
4.44%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Reiterates: Buy | $85 | $68.74 | +23.65% | 11 | Mar 9, 2026 | |
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $9.12 | +108.33% | 5 | Feb 26, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $240.38 | +58.08% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $175.45 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $29.39 | +83.74% | 8 | Feb 18, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $3.24 | +363.68% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $84.26 | +22.24% | 3 | Feb 11, 2026 | |
| BSX Boston Scientific | Reiterates: Buy | $110 | $71.90 | +52.99% | 16 | Feb 9, 2026 | |
| EMBC Embecta | Reiterates: Buy | $25 | $9.23 | +170.86% | 4 | Feb 6, 2026 | |
| HAE Haemonetics | Reiterates: Buy | $88 | $64.23 | +37.01% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.49 | +307.66% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $18.28 | +64.11% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $112.65 | +24.28% | 15 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $23.44 | +36.52% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $123.75 | +73.74% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.67 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $69.06 | -5.88% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.86 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.32 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.31 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $356.34 | -98.32% | 1 | Apr 9, 2020 |
DexCom
Mar 9, 2026
Reiterates: Buy
Price Target: $85
Current: $68.74
Upside: +23.65%
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $9.12
Upside: +108.33%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $240.38
Upside: +58.08%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $175.45
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $29.39
Upside: +83.74%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.24
Upside: +363.68%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $84.26
Upside: +22.24%
Boston Scientific
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $71.90
Upside: +52.99%
Embecta
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $9.23
Upside: +170.86%
Haemonetics
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $64.23
Upside: +37.01%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.49
Upside: +307.66%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $18.28
Upside: +64.11%
Jan 23, 2026
Maintains: Buy
Price Target: $145 → $140
Current: $112.65
Upside: +24.28%
Nov 18, 2025
Initiates: Buy
Price Target: $32
Current: $23.44
Upside: +36.52%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $123.75
Upside: +73.74%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.67
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $69.06
Upside: -5.88%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.86
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.31
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $356.34
Upside: -98.32%